Chemomab Reports Positive Phase 2 Data For Nebokitug In Primary Sclerosing Cholangitis

(RTTNews) - Chemomab Therapeutics, Ltd. (CMMB) Thursday reported positive results from the open-label extension (OLE) portion of the Phase 2 SPRING study evaluating nebokitug as a treatment for patients with primary sclerosing cholangitis (PSC), a chronic liver disease.

OLE participants who had been in the treatment arms of the 15-week SPRING trial received another 33 weeks of treatment with nebokitug, for a total of up to 48 weeks of treatment.

The OLE study confirmed that treatment with nebokitug for 48 weeks resulted in continued improvements across key biomarkers of liver injury, inflammation and fibrosis, including ELF score, fibrosis-related ELF score components and PRO-C3. Patients treated with nebokitug for 48 weeks showed a significantly lower progression of liver stiffness as well as decrease in number of clinical events compared to matching historical controls. Further, the drug candidate was well tolerated.

"We believe these positive results represent an important milestone for nebokitug, providing further clinical proof-of-concept in PSC and derisking our Phase 3 program," said Adi Mor, co-founder and Chief Executive Officer of Chemomab.